3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced/Metastatic Solid Tumors
1
Interventions
Capecitabine
27
pembrolizumab
19
Oxaliplatin
19
Fluorouracil
17
Cisplatin
17
Trastuzumab
14
Docetaxel
14
Leucovorin
11
Paclitaxel
8
Irinotecan
8
S 1 (combination)
7
Epirubicin
6
Cyclophosphamide
5
tegafur-gimeracil-oteracil
4
aldesleukin
4
Hyperthermic Intraperitoneal Chemotherapy
4
titanium silicide
3
spartalizumab
3
fludarabine phosphate
3
fludarabine
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Ramucirumab
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
Ado-Trastuzumab Emtansine
3
vistusertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Stomach Neoplasms
×
utomilumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts